Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert
This study has been completed.
Sponsor:
University of Pennsylvania
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00880932
First received: April 13, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribers in the control group.
| Condition | Intervention |
|---|---|
|
Warfarin and NSAID |
Behavioral: Electronic Alert |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Single Blind (Caregiver) |
| Official Title: | The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID |
Resource links provided by NLM:
Further study details as provided by University of Pennsylvania:
Primary Outcome Measures:
- Decreased rate of prescription of the combination of warfarin and NSAID [ Time Frame: 17 months ] [ Designated as safety issue: Yes ]
| Enrollment: | 1865 |
| Study Start Date: | August 2006 |
| Study Completion Date: | December 2007 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: customized electronic alert
This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a "reason for override" whenever the combination drugs of warfarin and NSAID were ordered together.
|
Behavioral: Electronic Alert |
|
No Intervention: Standard practice
The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
|
Eligibility| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- All resident physicians (RP) and nurse practitioners (NP) involved in inpatient care at two hospitals of the University of Pennsylvania
Exclusion Criteria:
- None
Contacts and Locations More Information
No publications provided
| Responsible Party: | UPenn School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00880932 History of Changes |
| Other Study ID Numbers: | 803787 |
| Study First Received: | April 13, 2009 |
| Last Updated: | April 13, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Pennsylvania:
|
warfarin NSAID The condition is the concomitant prescription of |
Additional relevant MeSH terms:
|
Anti-Inflammatory Agents Anti-Inflammatory Agents, Non-Steroidal Warfarin Therapeutic Uses Pharmacologic Actions Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Antirheumatic Agents Anticoagulants Hematologic Agents |
ClinicalTrials.gov processed this record on May 22, 2013